Review Article Open Access
Volume 2 | Issue 3 | DOI: https://doi.org/10.33696/immunology.2.025

Breast Implant-associated Anaplastic Large Cell Lymphoma: A Review with Emphasis on the Role of Brentuximab Vedotin

  • 11Department of Internal Medicine, Temple University Hospital, Philadelphia, PA, USA
  • 2Department of Medicine, section of Hematology, Temple University Hospital, Philadelphia, PA, USA
  • 3Department of Hematology and Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
+ Affiliations - Affiliations

Corresponding Author

Anthony Stack, anthony.stack@tuhs.temple.edu

Received Date: March 03, 2020

Accepted Date: March 26, 2020


Breast implant-associated anaplastic large cell lymphoma is a recently recognized complication of textured breast implants. It typically presents as unilateral peri-implant swelling approximately 7-10 years after implantation. While the course is usually indolent, breast implant-associated anaplastic large cell lymphoma may form a locally invasive mass and metastasize to regional lymph nodes or beyond to distant sites. Surgical excision has been well established as the standard of care for localized disease; however, guidelines directing management of advanced, recurrent or unresectable disease are based on limited and extrapolated evidence. The CD30-targeting immunoconjugate, brentuximab vedotin, has been utilized in this setting, typically in combination with chemotherapy. We recently reported a patient with unresectable breast implant-associated anaplastic large cell lymphoma who was treated with brentuximab vedotin monotherapy and has now sustained complete remission for 2.6 years. Herein, we provide an up-to-date review of the epidemiology, pathogenesis, clinical features, diagnosis and management of breast implant associated anaplastic large cell lymphoma with emphasis on the role of brentuximab vedotin.



Lymphoma, ALCL, Brentuximab vedotin, Breast Implant associated Anaplastic Large Cell Lymphoma, BIA-ALCL

Author Information X